Introduction {#S0001}
============

Thyroid cancer is the most common malignancy in endocrine-related tumors. In recent years, thyroid cancer has been well concerned because of the rapid rise in its incidence.[@CIT0001] As a first-line drug applied for T2DM (type 2 diabetes mellitus), metformin contributes to stabilize blood glucose levels through inhibiting gluconeogenesis and reducing hepatic glycogenolysis.[@CIT0002] Interestingly, the application of metformin sharply decreases the incidences of tumor diseases, suppresses the growth of malignant cells and enhances chemotherapy-sensitivity.[@CIT0003] Therefore, metformin may exert a potential anti-tumor role. It is expected to be an adjuvant drug for the treatment of thyroid cancer.

LRP2 is a unique transmembrane receptor belonging to the family of low-density lipoprotein receptors (LDLR). It is highly similar to other members of the LDLR family in the structure.[@CIT0004] As a multi-ligand receptor, LRP2 interacts with lipoproteins, vitamin-binding proteins, hormones and enzymes based on its complement-like sequences, thus participating in transmembrane transport and re-absorption of multiple substances.[@CIT0005] Mutations in the LRP2 gene are closely related to plasma cholesterol and low-density lipoprotein levels.[@CIT0006] Therefore, LRP2 is able to regulate lipoprotein metabolism.

The c-Jun N-terminal kinases (JNK) signaling pathway is one of the critical members of the mitogen-activated protein kinase (MAPK) family.[@CIT0007] JNK is mainly expressed in the cytoplasm. Once it is activated, cytoplasmic JNK rapidly translocates into the nucleus and further activates transcription factors c-JUN and AP-1.[@CIT0008],[@CIT0009] As a result, abundant apoptosis-related genes are activated.[@CIT0010] Meanwhile, the inflammatory response is activated as well.[@CIT0011],[@CIT0012] In this paper, we mainly explored the regulatory effect of metformin on the proliferative and apoptotic changes in TPC-1 cells and the involvement of LRP2 and the JNK pathway.

Materials and Methods {#S0002}
=====================

Cell Culture {#S0002-S2001}
------------

Human thyroid cancer TPC-1 cells were cultured in Roswell Park Memorial Institute 1640 (RPMI 1640) (HyClone, South Logan, UT, USA) containing 10% fetal bovine serum (FBS) (Gibco, Rockville, MD, USA), 100 μg/mL penicillin and 0.1 mg/mL streptomycin, in a 37°C, 5% CO~2~ incubator. Cultured cells displayed monolayer growth. Cell passage was conducted by 0.25% trypsin.

Cell Counting Kit-8 (CCK-8) {#S0002-S2002}
---------------------------

One hundred microliters of cell suspension (5--8×10^4^/mL) was applied in the 96-well plate and cultured overnight. On the other day, cells were treated with different doses of metformin for different time points. Absorbance (A) at 450 nm was recorded at the appointed time points using the CCK-8 kit (Dojindo Laboratories, Kumamoto, Japan) for depicting the viability curves.

Apoptosis Determination {#S0002-S2003}
-----------------------

Cells were washed with phosphate-buffered saline (PBS) twice, centrifuged at 3000 r/min for 5 min and prepared for suspension (5×10^4^/mL). Cell suspension was diluted in 500 μL of binding buffer, incubated with 5 μL of Annexin V in dark for 15 min, and 5 μL of Propidium Iodide (PI) at 4°C, in the dark for another 15 min. After 5-min centrifugation at 3000 r/min, the precipitant was dissolved in 300 μL of binding buffer and subjected to flow cytometry.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) {#S0002-S2004}
----------------------------------------------------------

Extraction of total RNA in cells was performed using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and RNA was subjected to reverse transcription. The extracted cDNA was applied for PCR using SYBR Green method (TaKaRa, Tokyo, Japan). Primer sequences were as follows: LRP2: F: 5′-GATCTGTGACCTTCATTCCTGGCCTGATC-3′, R: 5′-GCCATGACACCTGTAGATGTGGTGCTGAATAATTGGTTAA-3′; Glyceraldehyde 3-phosphate dehydrogenase (GAPDH): F: 5′-ACTGCCACCCAGAAGACT-3′, R: 5ʹ-GCTCAGTGTAGCCCAGGAT-3′.

Western Blot {#S0002-S2005}
------------

Total protein was extracted from cells using radioimmunoprecipitation assay (RIPA) lysis butter and quantified by bicinchoninic acid (BCA) method (Beyotime, Shanghai, China). Protein sample was loaded for electrophoresis and transferred on polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). After blocking non-specific antigens in 5% skim milk for 2 hrs, membranes were subjected to incubation with primary and secondary antibodies. Bands were exposed by chemiluminescence (ECL) reagents and analyzed by Image Software (NIH, Bethesda, MD, USA).

Transfection {#S0002-S2006}
------------

The cells were detached in 0.25% trypsin and prepared for suspension (5×10^4^/mL). Fifty pmol transfection vector and 2 μL of Lipofectamine^TM^ 3000 (Invitrogen, Carlsbad, CA, USA) were, respectively, diluted in 100 μL of Opti-MEM^®^ I. After 5-min maintenance at room temperature, they were mixed and let stand for another 20 min. Subsequently, the mixture was applied to the suspension. Transfected cells for 48 h were harvested for functional experiments.

Statistical Analysis {#S0002-S2007}
--------------------

Statistical Product and Service Solutions (SPSS) 20.0 (IBM, Armonk, NY, USA) was used for data analyses. Data were expressed as mean ± standard deviation. The differences among groups were statistically evaluated using Student's *t*-test when comparing only two groups or one-way analysis of variance (ANOVA) when comparing more than two groups. *P*\<0.05 was considered as statistically significant.

Results {#S0003}
=======

Metformin Suppressed Proliferation and Induced Apoptosis in TPC-1 Cells {#S0003-S2001}
-----------------------------------------------------------------------

TPC-1 cells were treated with 0, 1.25, 2.5, 5.0, 10.0 or 20.0 mM metformin for 24 or 48 h, respectively. As CCK-8 assay results revealed, the viability concentration-dependently decreased either after 24 or 48 h treatment ([Figure 1A](#F0001){ref-type="fig"}). In addition, the apoptotic rate in TPC-1 cells treated with 0, 10.0 or 20.0 mM metformin for 48 h gradually increased ([Figure 1B](#F0001){ref-type="fig"}). The above data supported the abilities of metformin to attenuate viability and induce apoptosis in TPC-1 cells.Figure 1Metformin suppressed proliferation and induced apoptosis in TPC-1 cells. (**A**) Viability in TPC-1 cells treated with 0, 1.25, 2.5, 5.0, 10.0 or 20.0 mM metformin for 24 or 48 h, respectively. (**B**) Apoptotic rate in TPC-1 cells treated with 0, 10.0 or 20.0 mM metformin for 48 h (n=3, \**p*\<0.05, significantly different from the 0 mM metformin group).

Metformin Application Downregulated LRP2 in TPC-1 Cells {#S0003-S2002}
-------------------------------------------------------

After treatment of 0, 10.0 or 20.0 mM metformin for 48 h, both protein and mRNA levels of LRP2 were downregulated, manifesting a dose--response relationship ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}).Figure 2Metformin application downregulated LRP2 in TPC-1 cells. (**A, B**) The mRNA (**A**) and protein (**B**) levels of LRP2 in TPC-1 cells treated with 0, 10.0 or 20.0 mM metformin for 48 h (n=3, \**p*\<0.05, significantly different from the 0 mM metformin group).

Metformin Application Inhibited the Activation of JNK Pathway in TPC-1 Cells {#S0003-S2003}
----------------------------------------------------------------------------

To clarify the involvement of the JNK pathway in metformin-mediated progression of thyroid cancer, protein levels of p-JNK1 and JNK1 were determined by Western blot. Protein level of p-JNK1 in TPC-1 cells was concentration-dependently downregulated by metformin treatment ([Figure 3](#F0003){ref-type="fig"}). However, the protein level of JNK1 remained unchangeable.Figure 3Metformin application inhibited the activation of JNK pathway in TPC-1 cells. Protein levels of p-JNK1 and JNK1 in TPC-1 cells treated with 0, 10.0 or 20.0 mM metformin for 48 h (n=3, \**p*\<0.05, significantly different from the 0 mM metformin group).

It is speculated that LRP2 was involved in the inactivation of JNK pathway. Subsequently, pcDNA-LRP2 was constructed. Transfection of pcDNA-LRP2 effectively downregulated both mRNA and protein levels of LRP2 in TPC-1 cells, showing a pronounced transfection efficacy ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}).Figure 4Transfection efficacy of pcDNA-LRP2. (**A, B**) The mRNA (**A**) and protein (**B**) levels of LRP2 in TPC-1 cells transfected with pcDNA-NC or pcDNA-LRP2 (n=3, \**p*\<0.05, significantly different from the control group).

Overexpression of LRP2 Abolished the Inhibitory Effects of Metformin on Cell Viability and Activation of the JNK Pathway {#S0003-S2004}
------------------------------------------------------------------------------------------------------------------------

Transfection of pcDNA-LRP2 markedly reversed the inhibitory effect of metformin on protein levels of LRP2 and p-JNK1 in TPC-1 cells ([Figure 5A](#F0005){ref-type="fig"}). Moreover, decreased viability in metformin-treated TPC-1 cells was partially reversed by overexpression of LRP2 ([Figure 5B](#F0005){ref-type="fig"}). It is verified that LRP2 was responsible for metformin-induced viability suppression and JNK pathway inactivation.Figure 5Overexpression of LRP2 abolished the inhibitory effects of metformin on cell viability and activation of the JNK pathway. TPC-1 cells were treated with NC, metformin or metformin+pcDNA-LRP2, respectively. (**A**) Protein levels of LRP2 and p-JNK1decreased significantly compared to the NC group, and overexpression of LRP2 reversed that. (**B**) Viability at 6, 24, 48, 72 and 96 h. Cell viability was decreased significantly compared to the NC group. Overexpression of LRP2 reversed this effect (n=3, \**p*\<0.05; significantly different from the NC group or overexpression of LRP2 plus metformin group).

Discussion {#S0004}
==========

A retrospective epidemiological study conducted by Evans et al[@CIT0013] in 2005 pointed out that the application of metformin markedly reduces the incidences of malignant tumors in patients with diabetes. Later, the tumor-suppressor effect of metformin has been well concerned. A relevant study demonstrated that metformin treatment suppresses tumor growth, elevates the complete remission rate and prolongs the disease-free survival in patients with thyroid cancer.[@CIT0014] Cho et al[@CIT0015] suggested that the application of different doses of metformin reduces the tumor volume and suppresses tumor cell growth in tumor-bearing nude mice. In a recent study, metformin like drug AICAR that affects cancer cell proliferation which in turn effective to create cell death in cancer cells via activating AMPK pathway.[@CIT0016] In this paper, metformin treatment markedly inhibited proliferative ability and induced apoptosis in TPC-1 cells. Furthermore, LRP2 level was downregulated and the JNK pathway was activated by metformin application.

The previous study has shown that LRP2 is mainly involved in regulations on lipoprotein transporter activity, low-density lipoprotein receptor activity, lipid metabolic process, lipoprotein transport, coronary vasculature development, aorta development, cell proliferation, ventricular septum development, clathrin-coated vesicle membrane, lysosome, etc. It is of significance in the etiology of acute myocardial infarction.[@CIT0017],[@CIT0018] The JNK pathway is extensively involved in cellular behaviors, and its dysregulation is considered to be linked to disease progression.[@CIT0019]--[@CIT0021] In MGC-803 cells (gastric cancer cells), JNK induces apoptosis through the mitochondrial pathway, triggering cytochrome release into the cytoplasm to initiate the apoptotic pathway.[@CIT0021],[@CIT0022] Besides, metformin is able to activate the AMPK, mTOR/6SK, p-ERK and p70S6K/pS6 pathways.[@CIT0014],[@CIT0023] It is capable of suppressing mitosis and proliferation of thyroid cancer stem cells and induces apoptosis.[@CIT0024] Our findings illustrated that metformin treatment inactivated the JNK pathway in TPC-1 cells, which could be abolished by overexpression of LRP2.

Collectively, metformin may be beneficial to inhibit the progression of thyroid cancer by downregulating LRP2 to inactivate the JNK pathway. Our findings provide new directions for the clinical treatment of thyroid cancer.

Conclusions {#S0005}
===========

Metformin treatment suppresses the proliferative ability and induces apoptosis of TPC-1 cells by downregulating LRP2 to block the JNK pathway.
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